What MBX Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 4 |
| Sells | 1 | 5 |
| Total trades | 3 | 19 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 99,000 | 1,182,984 |
| Disposed | 370 | 71,211 |
| Net activity | +98,630 | +1,111,773 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Chief Medical Officer | Aug 04 | Sale for tax withholding · S | −370 | $65.77 | −$24.3K | 14,399 |
| Hoerter Steven L. | President and CEO | Aug 03 | Grant / award · A | +71,000 | — | — | 82,938 |
| Smither John W | Chief Financial Officer | Aug 03 | Grant / award · A | +28,000 | — | — | 28,000 |
| Azoulay Salomon | Chief Medical Officer | May 08 | Disclosed 10b5-1 sale · S | −15,003 | $38.30 | −$575K | 14,769 |
| Azoulay Salomon | Chief Medical Officer | May 08 | Exercise / conversion · M | +15,003 | $16.00 | +$240K | 29,772 |
| Azoulay Salomon | Chief Medical Officer | May 08 | Disclosed 10b5-1 sale · S | −55,000 | $38.38 | −$2.11M | 14,769 |
| Azoulay Salomon | Chief Medical Officer | May 08 | Exercise / conversion · M | +55,000 | $10.46 | +$575K | 69,769 |
| Hawryluk P. Kent | President & CEO | May 06 | Open-market sale · S | −607 | $29.54 | −$17.9K | 727,667 |
| Azoulay Salomon | Chief Medical Officer | May 06 | Sale for tax withholding · S | −231 | $29.54 | −$6.82K | 14,769 |
| Hoerter Steven L. | Director | May 01 | Grant / award · A | +11,938 | — | — | 11,938 |
| Hawryluk P. Kent | President & CEO | Mar 13 | Open-market buy · P | +18,500 | $28.41 | +$526K | 486,777 |
| Hawryluk P. Kent | President & CEO | Feb 26 | Exercise / conversion · M | +28,768 | $16.00 | +$460K | 728,274 |
| Hawryluk P. Kent | President & CEO | Feb 02 | Grant / award · A | +35,250 | — | — | 699,506 |
| Bartram Richard | Chief Financial Officer | Feb 02 | Grant / award · A | +15,000 | — | — | 15,000 |
| Azoulay Salomon | Chief Medical Officer | Feb 02 | Grant / award · A | +15,000 | — | — | 15,000 |
| Hawryluk P. Kent | President & CEO | Oct 24 | Exercise / conversion · M | +182,859 | $3.25 | +$594K | 664,256 |
| Hawryluk P. Kent | President & CEO | Oct 20 | Open-market buy · P | +20,000 | $13.64 | +$273K | 468,277 |
| Hoerter Steven L. | Director | Oct 17 | Open-market buy · P | +20,000 | $13.25 | +$265K | 20,000 |
| Heron Patrick J | Director | Sep 26 | Open-market buy · P | +666,666 | $18.00 | +$12M | 5,219,440 |
| Pescovitz Ora H. | Director | Apr 08 | Open-market buy · P | +7,693 | $5.89 | +$45.3K | 24,329 |
Loading...
